Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...

Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 4:00 PM ETCompany ParticipantsBrian Foard - Executive VP ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Global Employee Stock Purchase Plan . Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 em ...